For the first act of the GLP-1 revolution, the scoreboard was brutally simple: how much weight came off? Every new drug presentation became a horse race measured in percentage points. Fifteen percent. Twenty percent. Twenty-five. The pharmaceutical industry learned that a bigger number could move billions of dollars in market value before a medicine ever reached a pharmacy shelf.
Now the scoreboard is changing.
The Muscle Numbers Are More Complicated Than the Headline
On September 30, Reuters reported mid-stage data suggesting that Regeneron’s experimental myostatin-blocking antibody trevogrumab could preserve substantially more lean mass when paired with semaglutide. Regeneron published detailed results on October 1. In the Phase 2 COURAGE trial involving nearly 1,000 adults with obesity, the 75-mg trevogrumab arm showed 68.9% less thigh-muscle-volume loss on MRI at 52 weeks compared with semaglutide alone. On a separate measure, DXA-assessed lean mass, the same dose preserved 42.5% of the lean mass that otherwise would have been lost at 52 weeks. Those are related but different measurements. The company is now positioning the program around what it calls the quality of weight loss.
That phrase is about to matter a lot.
Weight is not one tissue. When someone loses 40 pounds, the scale does not tell you how much came from fat, muscle, water or glycogen. GLP-1 therapies have produced extraordinary reductions in body weight, but clinical studies have also made clear that a portion of that loss can be lean tissue. And lean mass is not identical to skeletal muscle. That is not automatically evidence that these drugs are harmful; lean mass commonly declines during significant weight loss by many methods. But in older adults, frail patients and anyone already carrying limited muscle reserves, the composition of the loss becomes clinically important.
A Second Drug to Defend What Weight Loss Takes Away
And where medicine discovers a problem, pharma discovers a market.
Trevogrumab inhibits myostatin, a protein involved in limiting skeletal-muscle growth. The theory is elegantly commercial: let a GLP-1 suppress appetite and drive fat loss while a second drug helps defend muscle. Regeneron also tested trevogrumab with garetosmab, another antibody aimed at muscle biology.
That more aggressive combination preserved even more lean mass but brought enough adverse effects that Regeneron abandoned the triple-drug approach, according to Reuters. Two participants in that treatment group died, although Regeneron said it had not identified a causal association between the treatment and those deaths. The combination also produced higher rates of adverse effects and treatment discontinuations. That detail matters. Biology rarely gives you a free lunch, even when the lunch has already been suppressed by semaglutide.
The Obesity Market Is Splitting Into New Battlegrounds
The strategic implications are bigger than one Regeneron program. Obesity treatment is beginning to fracture into submarkets. One drug may win on maximum weight loss. Another may win on tolerability. Oral therapies may win on convenience. Amylin drugs may offer a different appetite-control profile. And muscle-preserving combinations may become especially attractive for older patients or people who cannot afford to sacrifice functional tissue while losing weight.
This is how a mature drug category behaves. The first generation proves that the biological target works. The next generation competes on everything the first generation did imperfectly.
Yesterday’s Blockbuster, Tomorrow’s Incomplete Solution
There is also a marketing lesson hiding in the science. For years, consumers were taught to worship the number on the scale. If body-composition preservation becomes a validated endpoint, drugmakers may soon teach those same consumers that the number was never enough.
Yesterday’s blockbuster can become tomorrow’s incomplete solution without changing a single molecule. All it takes is a better question.
What the Evidence Still Doesn’t Prove
The important caveat is that these are trial results for an investigational drug, not proof that every person taking semaglutide needs a muscle-preserving antibody. Trevogrumab has not been approved for treating obesity. Resistance training, adequate protein intake, age, baseline health and the pace of weight loss all matter. The clinical significance of preserving a given amount of lean mass must ultimately be judged by outcomes that matter to patients: strength, mobility, function, falls and long-term health.
But commercially, the signal is already loud. The obesity gold rush started with a promise to make people smaller. Its next frontier may be convincing them that smaller is not enough.
